Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0044-1785489
Post-COVID-19 Rhino-Orbito-Maxillary Mucormycosis Defect: Our Surgical Experience with Single Stage Delayed Reconstruction Using Free Flap
![](https://www.thieme-connect.de/media/10.1055-s-00042863/EFirst/lookinside/thumbnails/10-1055-s-0044-1785489_2382355-1.jpg)
Abstract
Introduction The effect of the second wave of COVID-19 was immense in India, specifically in the form of vicious COVID-19-associated mucormycosis. A higher number of radical debridements are required for disease control in combination with antifungal drugs in cases of COVID-19-associated mucormycosis, which results in complex maxillofacial defects. We aimed to evaluate the clinical outcomes in patients with rhino-orbito-maxillary defects due to COVID-19-associated mucormycosis undergoing a single stage delayed free flap reconstruction.
Methodology This prospective, single-center, multisurgeon study was performed on eight patients with COVID-19-associated rhino-orbito-maxillary mucormycosis in the department of burns and plastic surgery. The postoperative clinical outcome was evaluated using the University of Washington Quality of Life Questionnaire for patient's quality of life (QOL), aesthetic numeric analog (ANA) scale for patient's satisfaction for aesthetics, and the functional intraoral Glasgow scale for speech and deglutition at 1 and 3 months.
Results The median age of the study patients was 40 years, with 75% of the patients being males. Diabetes mellitus (DM) was present in all the patients. Mucormycosis was diagnosed within the first 3 months of COVID-19 infection. Maxillary defect was present in 62.5% of patients, out of which 50% had bilateral maxillary defects. There was significant improvement in the QOL and the aesthetics of patients from 1 to 3 months (p < 0.001). Speech and deglutition were also improved at 3 months, but the difference was not statistically significant.
Conclusion Single stage delayed free flap reconstruction can be advocated in patients with COVID-19-associated rhino-orbito-maxillary mucormycosis defect as there is considerable improvement in patients' QOL, aesthetics, speech, and deglutition over a period of time.
Publication History
Article published online:
23 April 2024
© 2024. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Cheruvu VPR, Khan MM. Reconstruction in rhino-orbito-cerebral mucormycosis survivors: a systematic review. Eplasty 2022; 22: e20
- 2 Singh P. Black fungus: here is a list of states with highest number of mucormycosis cases. Hindustan Times. Published May 21, 2021. Accessed June 17, 2021 at: https://www.hindustantimes.com/india-news/black-fungus-states-with-highest-number-of-mucormycosis-cases-101621559394002.html
- 3 Zee Media Bureau. 28,252 mucormycosis cases with 86% history of COVID from 28 states/UTs: Harsh Vardhan. Zee News. Published June 7, 2021. Accessed June 17, 2021 at: https://zeenews.india.com/india/28252-mucormycosis-cases-with-86-history-of-covid-from-28-states/uts-harsh-vardhan-2367455.html
- 4 Agrawal A, Dixit Y, Yonati V, Nigam P, Kheti P. Imaging of COVID-19-associated rhino-orbital-cerebral mucormycosis: imaging analysis of 120 patients. Egypt J Otolaryngol 2022; 38: 154
- 5 Sneha A, Kumar M P S, Krishnan M, Dhasarathan P. O R Muralidoss H. Resection and rehabilitation for COVID-19 associated rhino-maxillary mucormycosis: a case report. Cureus 2023; 15 (05) e39670
- 6 Balushi AA, Ajmi AA, Sinani QA. et al. COVID-19-associated mucormycosis: an opportunistic fungal infection. A case series and review. Int J Infect Dis 2022; 121: 203-210
- 7 Ravi MB, Srinivas S, Silina E, Sengupta S, Tekwani T, Achar RR. Prosthetic rehabilitation of rhino orbital mucormycosis associated with COVID-19: a case series. Clin Cosmet Investig Dent 2022; 14: 1-10
- 8 Roushdy T, Hamid E. A case series of post COVID-19 mucormycosis-a neurological prospective. Egypt J Neurol Psychiat Neurosurg 2021; 57 (01) 100
- 9 Saad RH, Mobarak FA. The diversity and outcome of post-covid mucormycosis: a case report. Int J Surg Case Rep 2021; 88: 106522
- 10 Rogers SN, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller Jr EA. The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002; 24 (06) 521-529
- 11 Bumbasirevic M, Stevanovic M, Bumbasirevic V. There are free fibular grafts. Int Orthop 2014; 38: 1277-1282
- 12 John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and Severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021; 7 (04) 298
- 13 Vekris BA. and others. Lower limb reconstruction involves the transfer of bones. Microsurgery 2011; 31 (03) 205-211
- 14 Hoenigl M, Seidel D, Carvalho A. et al; ECMM and ISHAM collaborators. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022; 3 (07) e543-e552
- 15 Sethi HS, Sen KK, Mohanty SS, Panda S, Krishna KR, Mali C. COVID-19-associated rhino-orbital mucormycosis (CAROM)—a case report. Egypt J Radiol Nucl Med 2021; 52: 165
- 16 Prakash H, Ghosh AK, Rudramurthy SM. et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol 2019; 57 (04) 395-402
- 17 Artopoulou II, Kalfarentzos E, Polyzois G, Perisanidis C. Prosthodontic restoration of a COVID-19 associated mucormycosis defect: a clinical report. Spec Care Dentist 2023; 43 (05) 696-700
- 18 Gupta S, Goil P, Mohammad A, Escandón JM. Mucormycosis management in COVID-19 era: is immediate surgical debridement and reconstruction the answer?. Arch Plast Surg 2022; 49 (03) 397-404